Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 7/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918956 | 1.00 | NR3C2 (0.45) | NR3C2KCNH2PARP1NR3C1ALDH1A1 | |
| SCHEMBL14341466 | 0.84 | NR3C2 (0.44) | NR3C2KCNH2PARP1NR3C1ALDH1A1 | |
| SCHEMBL30918983 | 0.84 | NR3C2 (0.44) | NR3C2KCNH2PARP1NR3C1MMP12 | |
| SCHEMBL12235340 | 0.84 | PARP1 (0.50) | NR3C2KCNH2PARP1NR3C1MMP12 | |
| SCHEMBL14476544 | 0.84 | NR3C2 (0.44) | NR3C2KCNH2PARP1NR3C1ALDH1A1 | |
| SCHEMBL5260878 | 0.80 | KCNH2 (0.43) | NR3C2KCNH2 | |
| SCHEMBL17956688 | 0.80 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL17970284 | 0.76 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL592791 | 0.76 | NR3C2 (0.47) | NR3C2KCNH2PARP1NR3C1ALDH1A1 | |
| SCHEMBL4343340 | 0.76 | NR3C2 (0.47) | NR3C2PARP1NR3C1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| EP-1399443-B1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2007-12-12 | — | — | EP | disclosed |
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. | 2007-06-14 | — | — | US | disclosed |
| US-7141564-B2 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | NRDC, NUCB2, NDC1 | NR3C2 2370/4885KCNH2 3311/4885PARP1 1657/4885 |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | NR3C2 3086/4885KCNH2 1381/4885PARP1 2112/4885 |
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | NRDC, NUCB2, NISCH | NR3C2 1932/4885KCNH2 2699/4885PARP1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.